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Abstract
Background: The blood brain barrier (BBB) and truncated trkB receptor on astrocytes prevent the penetration of brain
derived neurotrophic factor (BDNF) applied into the peripheral (PNS) and central nervous system (CNS) thus restrict its
application in the treatment of nervous diseases. As BDNF is anterogradely transported by axons, we propose that
peripherally derived and/or applied BDNF may act on the regeneration of central axons of ascending sensory neurons.
Methodology/Principal Findings: The present study aimed to test the hypothesis by using conditioning lesion of the sciatic
nerve as a model to increase the expression of endogenous BDNF in sensory neurons and by injecting exogenous BDNF into
the peripheral nerve or tissues. Here we showed that most of regenerating sensory neurons expressed BDNF and p-CREB
but not p75NTR. Conditioning-lesion induced regeneration of ascending sensory neuron and the increase in the number of
p-Erk positive and GAP-43 positive neurons was blocked by the injection of the BDNF antiserum in the periphery. Enhanced
neurite outgrowth of dorsal root ganglia (DRG) neurons in vitro by conditioning lesion was also inhibited by the
neutralization with the BDNF antiserum. The delivery of exogenous BDNF into the sciatic nerve or the footpad significantly
increased the number of regenerating DRG neurons and regenerating sensory axons in the injured spinal cord. In a
contusion injury model, an injection of BDNF into the footpad promoted recovery of motor functions.
Conclusions/Significance: Our data suggest that endogenous BDNF in DRG and spinal cord is required for the enhanced
regeneration of ascending sensory neurons after conditioning lesion of sciatic nerve and peripherally applied BDNF may
have therapeutic effects on the spinal cord injury.
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Introduction
Neurotrophins play critical roles in the development of nervous
system and synaptic plasticity in the adult [1,2]. They protect
neurons from degeneration and promote regeneration of injured
nerve and enhance differentiation of neural stem cells by activating
tyrosine kinase receptors (trk) and the down-stream signal
pathways [3,4,5]. Therefore it is believed that neurotrophins are
potential therapeutic drugs for the disorders of PNS and CNS [6].
However, neurotrophins applied systemically cannot reach
diseased nerve tissues in the brain and spinal cord due to the
BBB and thus its application as therapeutics is significantly
restricted. Furthermore, as the truncated trkB receptor in astroglia
acts as a negative regulator to prevent the diffusion of BDNF in the
CNS [7,8], even direct application of BDNF into the injured CNS
may not be effective on the prevention of apoptosis of neurons and
on the regeneration of injured nerve [9,10].
BDNF is a unique neurotrophin which is synthesized by
neurons and anterogradely transported [11,12,13] and is likely
transsynaptically transfered from neurons to neurons [14]. For
example, BDNF which is injected into the retina can be
internalized by retinal ganglion neurons and transported into the
superior colliculus, released and transferred to the postsynaptic
neurons[15]. BDNF applied to the peripheral nerve is transgan-
glionically transported into the spinal cord [16]. This axonal
transport property of BDNF may allow an opportunity to apply
BDNF as a therapeutic molecule to treat the disorders of CNS by
injecting it into the peripheral nerves or peripheral tissues.
The failure of adult CNS axons to regenerate after injury is due
to the non-permissive environment within CNS [17,18]. Strategies
to improve intrinsic neural capacity of regeneration or to over-
come inhibitory environment in the CNS will be of great value for
the therapy of spinal cord injury. The central axons in the dorsal
roots of primary sensory neurons could regenerate if the corres-
ponding peripheral axons were also injured one week earlier [19]
[20,21] [22]. However, the mechanisms underlying the enhanced
regeneration are not fully known. The elevation in the intracellular
cAMP level [23,24,25], upregulation of growth associated protein
gene GAP43 [22] and interleukin-6/the STAT signal pathway
play critical roles in the enhanced regeneration of ascending sen-
sory neurons after conditioning lesion of sciatic nerve [26,27,28].
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In the present study, we hypothesize that BDNF from the
periphery may have therapeutic effects on the injured spinal cord.
We attempt to test this hypothesis by examining effect of sensory
neuron-derived endogenous BDNF on the regeneration of
ascending sensory neurons. We use sensory neurons as the model
for the following reasons. First, sensory neurons straddle
peripheral and central nervous systems and thus can bypass the
BBB when BDNF is applied to the peripheral nerves. Secondly,
following peripheral nerve injury, BDNF is upregulated in sensory
neurons [12,29,30,31] and the upregulation of BDNF causes an
increased anterograde transport of BDNF into the spinal cord
[11,13,32]. Thirdly, sensory neurons express BDNF receptors
trkB, trkC and p75NTR [33,34] which are essential for the
internalization and axonal transport of BDNF. Fourthly, the role
of BDNF in the regeneration of sensory neurons in the spinal cord
is controversial as several previous studies showed that the delivery
of exogenous BDNF into the spinal cord does not promote the
regeneration of dorsal root into the spinal cord [9,10], most likely
due to the suppressive sequestration by truncated trkB on
astrocytes. In the present study, we also examined the effects of
exogenous BDNF injected into the sciatic nerve or peripheral
tissues (footpad) on the regeneration of ascending sensory neurons
and on the functional recovery after spinal cord injury. We found
that in contrast to the application of BDNF into the spinal cord,
peripherally derived (applied) BDNF is effective in promoting the
regeneration of ascending sensory neurons and functional
recovery. We propose that peripherally derived BDNF may have
a therapeutic potential for the spinal cord injury.
Results
Upregulation of BDNF immunoreactivity in the spinal
cord and DRG on the conditioning lesion side
Immunohistochemical examination of spinal cord specimens
showed that the BDNF expression was different in animals with or
without preconditioning lesion (Figure. 1). The BDNF-immuno-
reactivity (ir) was mainly distributed in the spinal cord caudal to
lesion site. BDNF-ir was located in both gray and white matter. In
the white matter BDNF-ir was present in axons with a club-like
shape, suggesting that BDNF was transported in the axons. Little
BDNF immunoreactivity was detected in the spinal cord rostral to
the lesion site in all animals (Fig. 1A and C). A few BDNF-ir nerve
fibres were detected in the caudal stump of injured cord without
conditioning lesion (Fig. 1 B). In contrast, in the rats with sciatic
nerve lesion one week before the spinal cord lesion, the number of
BDNF-ir axons was increased in the caudal stump (Fig 1 D),
compared with animals without sciatic nerve lesion.
Seven days after sciatic nerve injury, BDNF immunoreactivity
was significantly increased in the ipsilateral DRG as demonstrated
by both the number of positive neurons and by the staining
intensity (Fig. 1 F and G). In the contralateral L5 DRG,
24.563.2% of sensory neurons were positive for BDNF and
BDNF positive neurons were mainly small and medium sized
neurons(Fig. 1 E and G). In contrast, in L5 DRG ipsilateral to the
sciatic nerve injury, 52.465.1% neurons were positive for BDNF.
Consistent with our previous report [12,31], most large neurons
became BDNF positive in response to the sciatic nerve injury.
BDNF concentrations in different parts of spinal cord and
DRG after injury
To quantify the level of BDNF at different regions of the spinal
cord and DRG, a standard curve for BDNF enzyme linked
immunoadsorbent assay (ELISA assay) was established. The
concentration of BDNF in the spinal cord segment caudal to
lesion site ipsilateral to preconditioning lesion side was
13.7462.01 pg/mg, which was higher than those of normal
spinal cord (10.3261.15 pg/mg) and other segments around
lesion site (P,0.05). For the lumbar enlargement of spinal cord,
the BDNF concentration of the segment ipsilateral to precondi-
tioning lesion side (13.9461.13 pg/mg) was higher than that of
the contralateral side (10.2861.57 pg/mg) (P,0.05) (Fig. 2 B).
The concentration of BDNF in the ipsilateral DRG
(8.6461.47 pg/mg) was also higher than that in the contralateral
(3.8061.21 pg/mg) (P,0.05) and normal DRG (2.1560.09 pg/
mg) (P,0.05). No significant difference in BDNF levels was found
between the contralateral and normal control DRG (P.0.05)
(Fig. 2 C). These results further confirm previous studies that
BDNF is upregulated in the DRG and spinal cord after sciatic
nerve lesion [12,31].
Regenerating neurons express BDNF and p-CREB but not
p75NTR
As cAMP and phosphorylated CREB (p-CREB) are down-
stream signaling molecules of BDNF which play an essential role
in the enhanced regeneration of ascending sensory neurons
promoted by conditioning sciatic nerve lesion, we tested whether
the regenerating sensory neurons express BDNF and p-CREB. To
do this, we retrogradely labeled regenerating neurons by injecting
Fast blue (FB) rostral to the injury site. The labeling of
regenerating neurons is highly specific as no or rare FB+ neurons
were detected in the contralateral DRG. As shown in Fig. 3C and
F, FB+ neurons were large-sized neurons (Fig, 3 C and F). Most
FB+ neurons were immunoreactive for BDNF (see arrow, Fig. 3
A). Statistical analyses from 5 rats showed 81.164.0% of FB
neurons were BDNF positive (Fig. 3 D and H). Consistent with the
expression of BDNF in large neurons, conditioning lesion
significantly increased the number of p-CREB+ neurons in L4
and L5 DRG (Fig. 3 E). In the contralateral DRG, only 6.562.0%
of neurons were p-CREB+(Data not shown) whereas in the
ipsilateral DRG, 37.463.5% of neurons were p-CREB+. Inter-
estingly, most FB+ neurons were also p-CREB+ (88.063.5% ,
Fig. 3 G and H). In contrast, consistent with our previous studies
[35] , sciatic nerve lesion resulted in the reduction in the number
of p75NTR+ neurons (see arrowheads, Fig. 3 B) in DRG and
increase in p75NTR+ satellite glia (see arrow, Fig. 3 B). Most FB+
neurons did not express or expressed very low level of p75NTR
(Only 2.360.6%, Fig. 3 H). No FB+ neurons expressed high levels
of p75NTR (see arrowheads, Fig. 3 D).
CTB labeling of dorsal column axons in preconditioning
lesioned rats treated with NSS or the antiserum to BDNF
In the uninjured control rats, Cholera Toxin B Subunit (CTB)
was transported transganglionically from sciatic nerve to the
gracile nucleus along dorsal column of spinal cord. CTB-ir was
observed in the gracile nucleus (Fig. 4 C). After spinal cord injury,
the transport of CTB was interrupted and no CTB labeled nerve
terminals were observed in the gracile nucleus indicating the
complete injury of ascending sensory neurons. A significant axonal
regeneration was observed in rats with a preconditioning lesion of
sciatic nerve, consistent with previous studies. The pattern of
axonal regeneration was similar between non-serum-treated rats
and normal sheep serum (NSS) treated rats. CTB-labeled
regenerating axons were found caudal to, within and rostral to
the cavity. Axon branching and sprouting were observed growing
into gray matter towards brainstem (Fig. 4 A). In the animals
treated with BDNF antiserum, axons were stopped before the
cavity and only very few axons grew short distance into the lesion
Peripheral BDNF on SCI
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site (Fig. 4 B). The lengths of axons from the caudal boundary of
the lesion site into the lesion in NSS treated rats are longer than
that of BDNF antiserum treated rats (P,0.01) (Fig. 4 D). No CTB
labeled terminals was found in the dorsal column nuclei in both
groups, indicating the dorsal column cut was complete. The sheep
BDNF neutralization antiserum used here was well characterized
Figure 1. Effects of conditioning lesion of sciatic nerve on the accumulation of BDNF-immunoreactivity (ir) in the injured spinal
cord stumps. The spinal cord of adult Sprague-Dawley rats were crushed one week after sciatic nerve transection (conditioning lesion). Rats were
allowed to survive 24 hours after spinal cord injury. The spinal cord sections were stained for BDNF. A and B: spinal cord sections rostral (A) and
caudal (B) to the lesion site, respectively, from a rat without conditioning lesion of sciatic nerve. C and D: spinal cord sections rostral (C) and caudal
(D) to lesion site, respectively, from a rat with conditioning lesion of sciatic nerve. More BDNF-positive fibres were found in the caudal stump of the
injured cord from rats with conditioning lesion (D) than that from rats without conditioning lesion (B). BDNF-ir was significantly increased in the
ipsilateral DRG as demonstrated by both the number of positive neurons and by the staining intensity (Fig. 1F and G ).** p,0.01 compared with
contralateral side DRG (n= 4). In the contralateral L5 DRG (Fig. 1E), BDNF positive neurons were mainly small and medium sized neurons. IL: ipsilateral,
CL: contralateral. Scale bar: 100 mm applies to A, B, C, D, E and F.
doi:10.1371/journal.pone.0001707.g001
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previously [36], widely used in vivo to examine physiological
functions of BDNF [36,37,38,39,40] and was demonstrated only
recognizing mature BDNF but not other neurotrophins [36]. To
further demonstrate its specificity, we did Western blot on all
neurotrophins. The results were consistent with our previous
studies and showed its specificity to only mature BDNF but not
other neurotrophins (Figure S1,).
Antiserum to BDNF decreases the number of FB labeled
neurons in the DRG
FB is widely used to retrogradely label neurons [41,42]. In this
study, FB was injected into the dorsal column 5 mm rostral to the
lesion site. When regenerating axons crossed the lesion site and
reached the FB injection site, the fluorescent dye was retrogradely
transported to the soma of these axons in the DRG. Contralateral
DRG was used as the negative control to monitor significant FB
leakage. In all these animals we did not see significant FB labeling
in the contralateral DRG. However a dramatic number of FB
labeled neurons was observed in the ipsilateral DRG after
conditioning lesion (Fig. 5 A). The percentage of FB positive
neurons in control rats without NSS treated was similar to that of
NSS treated animals (data not shown).
In the ipsilateral DRG, the number of FB-labeled regenerating
neurons was significantly reduced in these BDNF antiserum-
treated rats, compared to those of NSS-treated animals (P,0.01)
(Fig. 5 A, C and E). In the DRG from the contralateral side in the
NSS and anti-BDNF groups, only very few neurons were labeled
by FB and there was no significant difference between the groups
(Fig. 5 B, D and E) (P.0.05). While 45.4469.58 neurons per
section were labeled in the ipsilateral DRG of rats treated with
NSS (Fig. 5 E), the number of labeled neurons in the ipsilateral
DRG in the rats treated with antiserum to BDNF was 562.98 per
section (Fig. 5 E).
We also examined roles of BDNF in the expression of
regeneration-related markers in sensory neurons: growth associat-
ed protein 43 (GAP-43) and signaling molecule phosphorylated
Erk (p-Erk) after conditioning lesion. One week following a lesion
of sciatic nerve in NSS treated DRG, the number of GAP-43+ and
p-Erk+ neurons was significantly increased compared to those in
the contralateral DRG (data not shown). p-Erk immunoreactivity
was present in both nuclei and cytoplasm (Fig. 6 A and E). A small
subpopulation of neurons was GAP-43+ in the ipsilateral DRG
(Fig. 6 B and F). Some of GAP-43 positive neurons in the
ipsilateral DRG were also p-Erk+ (Fig. 6 D and H). After
treatment with the BDNF anti-serum, the number of GAP-43+
and p- Erk + neurons were counted and calculated against total
number of neurons. The numbers of p-Erk and GAP-43 positive
neurons after anti-BDNF serum treatment in the ipsilateral DRG
were significantly reduced (Table 1).
As sciatic nerve injury can cause the death of sensory neurons in
adult rats [43,44] and BDNF antibody treatment aggravates the
death [43,44], it is possible that the death of sensory neurons
contributed to the lack of retrograde FB labeling. To test this idea,
we injected FB to the dorsal column caudal to the lesion site in a
separate experiment and counted the number of FB labeled
neurons in L5 DRG. The data showed there was no significant
difference in the number of labeled FB neurons between the
antibody treated and the NSS treated group (Figure S2). The data
suggest that the BDNF antiserum may not affect the death of
ascending large sensory neurons and the lack of the regeneration
in the BDNF antiserum treated group was not due to the death of
axotomized sensory neurons. Our data was consistent with
previous reports showing that the sciatic nerve lesion mainly
causes the death of small sensory neurons but not large sensory
neurons [43,44].
The Antiserum to BDNF retarded the neurite outgrowth
in vitro
After sciatic nerve transection, DRG neurons increase their
growth propensity and can extend much longer neurites in vitro. To
see whether the enhanced neurite outgrowth was promoted by
endogenous BDNF, we examined the neurite outgrowth in the
presence of the sheep antibody to BDNF. After being cultured for
24 hours, the neurite from ipsilateral DRG with conditioning
lesion grew significantly longer than those from the ispilateral non-
conditioning lesioned DRG. More neurites and less arborization
were detected in neurons from the preconditioning DRG than
those from the non-conditioning lesioned DRG neuron. In the
ipsilateral DRG with the preconditioning nerve lesion, the length
Figure 2. Histograms show BDNF levels in different regions of
the injured spinal cord and DRG after conditioning lesion of
sciatic nerve. One week after sciatic nerve transection, the spinal cord
of adult rats were crushed and the rats were allowed to survive
24 hours before the fresh tissues were dissected for measurement of
BDNF levels with two-site ELISA. Panel A: Schematic diagram showing
different regions of spinal cord tissues dissected for ELISA. Segments A,
B, E are in ipsilateral side of the conditioning lesion. Segments C, D, F
are in the contralateral side. Segments A and C are rostral to spinal cord
lesion site and segments B, D are caudal to spinal cord lesion site.
Segments E and F are in lumbar enlargement of spinal cord. Panel B
shows BDNF levels in different regions of injured spinal cord after
conditioning lesion. The columns A, B, C, D, E, and F are as indicated in
Panel A; Control is the corresponding thoracic spinal cord segment
from normal animals. Panel C: BDNF levels in DRG with or without
preconditioning lesion. Data were expressed as Mean6S.E.M. *P,0.05
in panel B compared with normal spinal cord (control) and other
segments around lesion site (A, C, D). ** P,0.05 in panel B compared
with that of the contralateral side ( F). *P,0.05 in panel C compared
with that in the contralateral and normal DRG (n= 8).
doi:10.1371/journal.pone.0001707.g002
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Figure 3. Retrograde tracing combined with immunohistochemistry of BDNF (green in A), p75NTR (red in B) or p-CREB(green in E).
FB+ neurons were blue- (C, F) and most of FB+ regenerating neurons were large-sized neurons. The section in Fig. 3A, B, C was triple-labeled with
BDNF and p75NTR. Most FB+ neurons were immunoreactive for BDNF (arrows in A and C ,H). Most FB+ neurons did not express p75NTR but some
were surrounded with p75NTR+ satellite glial cells (arrows, B, C and D). Neurons expressing significant level of p75NTR were not FB+ (arrowheads, B,
C and D). A subpopulation of large sensory neurons was p-CREB+ (E, green). Most FB+ neurons were also p-CREB+ (E and G). H: Group data showed
the colocalization percentage of FB+ neurons with BDNF, p-CREB or p75NTR, respectively (n = 5). Scale bar = 100 mm in D applies to A, B, C. Scale
bar = 50 mm in G applies to E, F.
doi:10.1371/journal.pone.0001707.g003
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of neurites from cultures containing BDNF antiserum
(160.69623.18 mm Fig. 7 D) were significantly shorter than those
of neurites from NSS treated group (350.60628.30 mm Fig. 7 B)
(*P,0.05, Fig. 7 B). In the contralateral DRG (Fig. 7 A and C), no
significant difference in neurite lengths was found between NSS-
treated (80.32616.35 mm, Fig. 7 A and E) and BDNF antibody-
treated DRG (74.13613.18 mm, P.0.05, Fig. 7 C and E.).
Antisera to BDNF retarded the neurite outgrowth of
explant cultures
The cultured DRG explants grew their neurites in the 3
dimensional Matrigel culture media. After being cultured for
48 hours, In the ipsilateral DRG with the preconditioning nerve
lesion, the length of neurites from cultures containing BDNF
antiserum (248.6632.19 mm, Figure S3C) were significantly
shorter than those of neurites from NSS treated group
(419.7623.90 mm, Figure S3A) (* P,0.05,). In the contralateral
DRG, no significant difference in neurite lengths was found
between NSS treated (153.69618.35 mm, Figure S3B) and
antiserum-treated DRG (183.59616.19 mm, Figure S3D,
P.0.05,).
Effects of exogenous BDNF on the regeneration of
injured sensory neurons in the spinal cord
Given that BDNF from sensory neurons is essential for the
enhanced regeneration after preconditioning lesion and that
BDNF is mainly derived from sensory neurons, we hypothesize
that exogenous BDNF introduced to sensory neurons may be
effective in promoting regeneration of sensory neurons after spinal
cord injury in naı¨ve animals. To test this hypothesis, we introduced
exogenous BDNF into the footpad with a bolus injection or into
the sciatic nerve by an Alzet osmotic pump. The results showed
that exogenous BDNF into the footpad significantly increased the
number of FB labeled (regenerating) neurons in the ipsilateral
DRG (Fig. 8 A). In contrast, no FB labeled neuron was detected in
the contralateral DRG (Fig. 8 B). No Fast Blue labeled neuron was
detected in the ipsilateral and contralateral DRG of BSA groups
(Fig. 8 C, D). In the animals receiving BDNF infusion into the
sciatic nerve with Alzet pumps for 7 days (3 days before and
4 days after the dorsal column lesion), more regenerating neurons
in DRG were seen in the sections from the ipsilateral DRG and no
or few of FB labeled neurons were detected in the contralateral
DRG and in the control group (data not shown). The group data
show significant differences in the average number of Fast Blue
labeled DRG neurons per section in the different groups (Fig. 8 E
and F).
Transport of labeled recombinant BDNF
To test whether exogenous BDNF is transported by the
peripheral nerves after injection into the footpad, we labeled
BDNF and BSA with biotin. Six hours after injecting 2 mg of
biotinylated BDNF into the footpad of adult rats, BDNF-
containing nerve fibres were detected in the epidermis of footpad
of injected side (Figure S4A). Three hours after injection, a
number of BDNF containing fibres and vesicles were detected in
the sciatic nerve (Figure S4B). Six hours after injection,
significantly more BDNF containing nerve fibres and varicosities
were detected in the sciatic nerve (Figure S4C). In contrast, no
fluorescent vesicles or fibres were detected in the sciatic nerve after
injection of labeled BSA into the footpad (Figure S4D).
Effects of exogenous BDNF on the expression of CGRP
and GAP-43 in the injured spinal cord
To see whether exogenous BDNF enhances axonal sprouting of
sensory neurons, we examined the sensory nerve marker CGRP in
injured spinal cord by immunohistochemistry. Five sections per
animal (n = 4) were included in the analysis.
In the dorsal column, a number of CGRP-ir fibres were
detected caudal and rostral to the injury site in both BDNF and
BSA injected rats. However, the number and density of CGRP
nerve fibres in the BDNF-treated group were significantly
Figure 4. Microphotographs show CTB labeled axons within
spinal dorsal column of rats after conditioning sciatic nerve
lesion and spinal cord injury.Micrographs (A and B) were captured in
the caudal–rostral orientation from left to right. A: In the rats of the NSS
treated group, CTB labeled axons (see double arrows) in dorsal column
were detected in the spinal cord central and rostral to lesion site along
the wall of the cyst resulted from spinal cord injury. B: In the rats of the
BDNF antiserum treated group, axons stopped caudal to lesion site (see
double arrows) and failed to regenerate into the cyst (see arrow). C: In the
rats without spinal cord injury, CTB was transported transganglionically
along dorsal column to label the terminals in the gracile nucleus. D: The
measurement of the length of CTB positive axons detected beyond the
caudal edge of the cysts. The enhanced axonal regeneration by sciatic
nerve lesion was substantially blocked by the treatment of the BDNF
antiserum. * P,0.01 compared with the NSS group (n= 5/group). Scale
bars: 100 mm, applies to A, B and C. Arrowhead: cavity of spinal lesion
site. Arrow: rostral side. Double arrows: CTB labeled axons.
doi:10.1371/journal.pone.0001707.g004
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increased compared with those in the BSA treated group. In
particular, more CGRP nerve fibres were detected in the vicinity
of injury cavity from BDNF injected rats (Figure S5A) compared
to rats treated with BSA (Figure S5F). Most importantly, a
significant number of thin CGRP fibres was detected within the
injury site in BDNF treated rats (Figure S5B, C, D, E), suggesting
growth of regenerating fibres into the injury site. In contrast, in all
cases examined, no CGRP-ir fibres were detected within the injury
site in rats injected with BSA (Figure S5F, H, I).
Similar results were obtained in GAP-43 stained sections. As
GAP-43 is involved in axonal growth, we used GAP-43 as a
supporting marker for axonal regeneration of all axons. Figure
S6A shows that BDNF-treated animals presented a higher
density and intensity of GAP-43 staining than those from BSA-
treated animals. The immunoreactivity was predominantly
observed in the area surrounding the cavity (see Figure S6A and
C). However, there were fewer GAP-43 immunopositive pro-
cesses across the hemitransection site in the BSA-treated group
(Figure S6C), and some GAP-43+ fibres were restricted to the gray
matter. These results were consistent among a total of 8 animals
examined.
Effects of exogenous BDNF injected into the footpad on
the locomotion recovery after contusion injury
All rats were fully paralyzed at day 0 and 1 day after the
moderate contusion injury and the rats showed no observable
movement or slight movement of one or two joints (BBB, 0–1) .
One week after injury, the rats in both groups exhibited partial
recovery. The recovery reached a relatively stable level by 2–
3 weeks after injury. Generally, the BBB scores in the BDNF
Figure 5. Effects of BDNF antiserum treatment on the number of regenerating sensory neurons (FB-labeled) in DRG after
conditioning sciatic nerve lesion and spinal cord injury. Regenerating neurons in the DRG were labeled by injecting FB into the spinal cord
rostral to the lesion site. A: A section from a DRG ipsilateral to the sciatic nerve lesion in a rat treated with NSS. B A section from a DRG contralateral
to the sciatic nerve lesion in the same rat as in A treated with NSS. C: A section from a DRG ipsilateral to the sciatic nerve lesion treated with the BDNF
antiserum. D: A section from a DRG contralateral to the sciatic nerve lesion in a rat treated with the BDNF antiserum. E: A histogram shows the effects
of BDNF antiserum treatment on the number of FB labeled neurons in DRG. Filled bar: DRG ipsilateral to the sciatic nerve lesion; Open bar: DRG
contralateral to the sciatic nerve lesion; * p,0.01 compared to normal sheep serum treated (NSS) rats (n = 10). IL: ipsilateral, CL: contralateral. Scale
bar: 100 mm.
doi:10.1371/journal.pone.0001707.g005
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group were better than those in the BSA group at 2, 3, 4, 5 and
6 weeks after SCI (Fig. 9). The motor function of the BDNF-
treated animals continued to improve 6 weeks after injury and the
scores in these animals reached .15, corresponding to consistent
weight-supported plantar steps with consistent forelimb–hindlimb
coordination plus parallel paw position at initial contact with the
testing surface. In contrast, control animals (n=7) reached a
plateau after 4 weeks at a BBB score of 12, which corresponds to
frequent weight supported plantar steps and occasional forelimb–
hindlimb coordination.
Discussion
The aim of the current study was to test the hypothesis that
peripherally derived and/or applied BDNF would enhance the
regeneration of central axons of sensory neurons in the injured
spinal cord. Two paradigms were used to test the hypothesis. The
first was to induce BDNF upregulation by lesioning sciatic nerve
and by using the BDNF neutralizing antibody to block peripheral
BDNF. The enhanced regeneration of sensory neurons by
conditioning sciatic nerve lesion was almost completely blocked
Figure 6. Effects of BDNF antiserum treatment on GAP-43 and p-Erk immunoreactivity in the DRG after preconditioning lesion. A,
B, C, D: a DRG section from a rat treated with NSS. E, F, G, H: a DRG section from a rat treated with the BDNF antiserum. A and E, B and F, or C and
G were stained with p-Erk (red), GAP-43( green), or DAPI (blue), respectively; D and H were merged images from A, B, C and E, F, G, respectively. p-
Erk immunoreactivity was present in both nuclei and cytoplasm (A and E). A small subpopulation of neurons was GAP-43+ in the ipsilateral DRG (B
and F). Some of GAP-43 positive neurons in the ipsilateral DRG were also p-Erk+ (D and H). Scale bar: 50 mm.
doi:10.1371/journal.pone.0001707.g006
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by peripheral injection of the BDNF antiserum. The second was to
deliver exogenous BDNF into the sciatic nerve or peripheral tissues
in the spinal cord injury model. Peripheral application of BDNF not
only promotes the regeneration of ascending sensory neurons but
also promotes the functional recovery after spinal cord injury.
The phenomenon that conditioning lesion increases the intrinsic
growth capability of adult sensory neurons was discovered many
years ago [45,46] and confirmed by studies using spinal cord
injury as a model [19,22]. These discoveries have generated great
interest because the conditioning lesion can be used as a model to
investigate the mechanisms of why CNS fails to regenerate after
injury. In the present study, we examined whether increased
expression of BDNF in sensory neurons plays a critical role in the
enhanced regeneration in this model. We found that in the
conditioning lesion model, most regenerated neurons express
Table 1. Effects of the BDNF antiserum treatment on the
expression of p-Erk and GAP-43 immunoreactivity in DRG after
sciatic nerve lesion (% of total neurons).
NSS (n =4) BDNF antiserum (n=4)
p-Erk 48.163.5 19.262.1*
GAP-43 21.264.3 8.462.7*
Immediately after sciatic nerve transection, rats received intraperitoneal
injection of the BDNF antiserum (10 ml/gram body weight, n = 4) or normal
sheep serum (n = 4). One week after the serum injection, DRG sections were
stained for GAP-43 and phosphorylated Erk. The number of GAP-43+ and p-Erk+
neurons were counted and calculated against total number of neurons.
*p,0.05 compared with the NSS group.
doi:10.1371/journal.pone.0001707.t001
Figure 7. The effects of BDNF antiserum on the neurite outgrowth of DRG in vitro. Ipsilateral (B,D) and contralateral(A, C) DRG one week
after the sciatic nerve lesion were dissected and cultured for 24 hours in the culture medium in the presence of NSS (A, B) or BDNF antiserum (C, D).
Dissociated DRG neurons were cultured for 24 h and then immunostained for b -tubulin. Scale bar, 100 mm. E: group data and statistical analysis of
neurite length. The length of neurites from cultures containing BDNF antiserum were significantly shorter than those of neurites from NSS -treated
group in the ipsilateral side DRG (*P,0.05, Student’s t test; n=5/group, E). IL: ipsilateral, CL: contralateral.
doi:10.1371/journal.pone.0001707.g007
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BDNF but not p75NTR. The neutralization of endogenous BDNF
with BDNF antibodies in vivo dramatically blocked the enhanced
regeneration of sensory neurons and reduced the expression of
GAP-43 in sensory neurons. Neurite growth assay in the presence
of BDNF antibody in vitro showed the significant reduction in the
neurite growth of conditioning lesioned DRG neurons.
Several pieces of evidence support the notion that peripherally
derived BDNF may play a role in the regeneration of ascending
sensory neurons. We found that BDNF is accumulated in the
spinal cord stump caudal to the lesion site. Quantitative data
showed that the level of BDNF was higher in the ipsilateral stump
caudal to the lesion site and in the ipsilateral lumbar spinal cord.
Figure 8. Effects of exogenous recombinant human BDNF delivered to the footpad or the sciatic nerve on the regeneration of
ascending primary sensory neurons in DRG after spinal cord injury in rats. Regenerating neurons in DRG were retrogradely labeled with FB.
A: More regenerating neurons in DRG can been seen in the section from the ipsilateral DRG in a BDNF delivered to footpad rat; B: A section from a
DRG contralateral DRG in the same rat as in A treated with exogenous BDNF. A few of FB+ neuron was detected in the section from the contralateral
DRG; C: A section from a ipsilateral DRG in a rat treated with the BSA to footpad; D: A section from a contralateral DRG in a rat treated with the BSA as
in C. E: A histogram shows the effects of exogenous BDNF treatment on the number of FB labeled neurons in DRG. ** p,0.01 compared to
contralateral side (n = 5) and BSA rats (n = 6). Scale bar: 100 mm. F: Group data show the average number of Fast Blue labeled DRG neurons per
section from the animals infused with exogenous BDNF and PBS into sciatic nerve respectively. * P,0.01 compared with contralateral DRG in BDNF
treated rat and in PBS treated rats (n = 5/group). IL: ipsilateral, CL: contralateral.
doi:10.1371/journal.pone.0001707.g008
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These results are consistent with increased expression of BDNF in
the DRG and spinal cord after sciatic nerve injury [12,31] and
consistent with the anterograde transport of BDNF [13,47].
Current data with ELISA assay technique also showed increased
level of BDNF in the ipsilateral DRG one week after sciatic nerve
lesion. The pattern of BDNF expression suggests that the increased
BDNF from spinal cord regions may be partially derived from the
anterograde transport from DRG. In fact, previous studies showed
that sciatic nerve lesion increased BDNF anterograde transport in
the sensory neurons [16]. The anterogradely transported BDNF is
likely released in the spinal cord [48].
After conditioning lesion and spinal cord injury, BDNF from
both spinal cord and DRG could be important for the enhanced
regeneration. To dissect the relative contribution of BDNF from
DRG, neurite growth assay was carried out in vitro. Our results
supported previous studies [22,49] where the conditioning lesion
reduced neurite arborization but resulted in straighter and longer
neurites. Suppression of enhanced neurite growth by the antibody
to BDNF in vitro indicates that BDNF was upregulated in injured
neurons and glia in the DRG and can be released into culture
medium to promote neurite growth via autocrine mechanisms
[50]. Consistent with a previous report [51], no effect of the
antiserum on neurite growth was seen in previously uninjured
DRG, suggesting that BDNF is not essential for neurite growth of
previously uninjured neurons. The 30–60% inhibition (Fig. 7 and
Figure S3) of neurite growth by the antiserum to BDNF in vitro was
smaller than that suppressed by them in vivo (Fig. 4 and Fig. 5),
suggesting that BDNF from other sources and/or other factors
that are regulated by BDNF also contribute to the enhanced
regeneration after conditioning sciatic nerve lesion. Endogenous
BDNF in vivo may have indirect actions on other cell types to
increase their expression of other neurotrophic factors as
demonstrated previously [52,53]. Other neurotrophic factors and
signal pathways are clearly involved in the enhanced regeneration
of spinal sensory neurons after conditioning lesion [26,27,28]. For
example, a reciprocal interaction between interleukin-6 and
BDNF may play important roles in the enhanced regeneration
after conditioning sciatic nerve lesion [54]. Application of
neurotrophins to cultured DRG neurons could not reproduce
the axon growth induced by a conditioning lesion while leukemia
inhibitory factors (LIF) promoted neurite outgrowth [55,56]. Thus
blockade of a single neurotrophin pathway may affect the
production of the total amount of neurotrophic factors which
influence the enhanced regeneration, as observed here and in
other studies [26].
We showed that the direct delivery of BDNF to the sciatic nerve
or footpad promoted the regeneration of sensory neurons and
functional recovery in the injured spinal cord. These results are
very exciting and surprising because the dogmatic view believes
peripherally-derived neurotrophic factor would not be able to act
on CNS. Furthermore, we found that injected BDNF into the
footpad accumulated within the nerve terminals and in the sciatic
nerve (Figure S4). Exogenous BDNF to the peripheral sensory
neurons would not only directly activate peripheral sensory
neurons and promote their regeneration after central axon injury,
but also could be transported transganglionically into the spinal
cord. The regeneration of ascending sensory neurons promoted by
peripheral administration of BDNF may have clinical significance
as an injection of BDNF into the footpad is simple and clinically
practical in patients. The surgical procedure and possible
inflammation due to the delivery process had no effect on the
regeneration. Whether the exogenous BDNF has any effects on
the regeneration of descending neurons needs further investiga-
tion, but this is likely as we found more GAP-43 labeled fibres in
the injury site in the BDNF treated group than the BSA group
(Figure S6).
Our results that exogenous BDNF is effective for the
regeneration of ascending sensory neurons after spinal cord injury
are in contrast with those of exogenous BDNF in a dorsal root
injury model [9,10], where the delivery of exogenous BDNF into
the spinal fluid had no effect on the regrowth of damaged axons
across the dorsal root entry zone and into the spinal cord [57].
Our finding is also in contrast to the recent study showing
endogenous trkB ligands (BDNF and NT4) suppress the functional
mechanosensory plasticity (sprouting) in the deafferented spinal
cord [58]. This contradiction may be due to the different capacity
in diffusion of BDNF in CNS and PNS. It is known that truncated
trkB expressed by astrocytes prevents the diffusion of BDNF into
the brain [7,8] whereas BDNF injected into periphery can freely
diffuse and acts on sensory nerves and terminals. The studies on
BDNF with other delivery methods further support this notion.
Genetically modified cells secreting BDNF promoted axonal
regrowth across transected adult rat spinal cord
[24,59,60,61,62,63]. In addition, BDNF directly delivered to cell
bodies was able to promote axonal regeneration in chronically
injured spinal cord [64]. These delivery methods for BDNF
overcome the diffusion barrier and thus showed positive roles for
the regeneration of the spinal cord.
BDNF may promote the regeneration of sensory neurons by
increasing intracellular cAMP and down-stream signal CREB
[65]. Intraganglionic cAMP injection can mimic the effect of
conditioning peripheral nerve lesion to promote the regeneration
of central branch in the injured spinal cord. Indeed the level of
cAMP in the DRG was increased after conditioning peripheral
lesion [24,25], and myelin associated glycoprotein (MAG)/myelin
no longer inhibited axonal growth, which is protein kinase A
(PKA)-dependent. Injection of cAMP into DRG can also mimic all
these effects [24]. It was reported previously that neurotrophins
elevated the intracellular levels of neuronal cAMP and neurons
primed with neurotrophins were able to overcome the growth
inhibition from MAG or myelin [23,66]. Most recently it was
discovered that neurotrophins activated extracellular signal-
regulated kinase (Erk) in a Trk-dependent way and activated Erk
Figure 9. Exogenous BDNF injected into the footpad improves
the locomotion behavioral recovery after a contusion injury in
rats. Graphs show the locomotor BBB scores in rats treated with BSA
(n=7) or BDNF (n = 7). There was significant improvement in the BBB
scores for treated vs. control rats on days 14, 21 ,28, 35 and 42 post-
injury (* p,0.05, Student’s t test). Values are means6SEM. The BBB
scores were assigned by two blinded observers.
doi:10.1371/journal.pone.0001707.g009
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inhibited phosphodiesterase-4 (PDE4). Inhibition of PDE4 allows
cAMP to be elevated and, consequently, to overcome axonal
growth inhibition from MAG or myelin [67]. In the present study,
we found that after conditioning sciatic nerve lesion the majority of
regenerating sensory neurons expressed BDNF and p-CREB but
not p75NTR. Our previous studies showed that sciatic nerve
transection significantly increased p75NTR in glia but decreased
p75NTR in neurons in the DRG [35]. p75NTR expression in glial
cells may have a role in nerve regeneration opposing that in
neurons [68,69]. Our data suggest that sciatic nerve lesion-induced
differential expression of p75NTR in neurons and glia [70] may
play a partial role in the enhanced regeneration of ascending
sensory neurons.
In summary, conditioning sciatic nerve lesion induced the
upregulation of BDNF in the DRG and in the injured spinal cord.
Blockade of endogenous BDNF in vitro and in vivo suppressed the
enhanced neurite growth and regeneration of sensory neurons
induced by conditioning lesion of the sciatic nerve. Peripheral
administration of exogenous BDNF promotes regeneration of
sensory neurons and functional recovery after spinal cord injury.
Endogenous BDNF plays an essential role in the enhanced
regeneration of injured ascending sensory neurons after condi-
tioning lesion of sciatic nerve and peripheral application of
exogenous BDNF promotes regeneration of sensory neurons and
functional recovery. It is concluded that peripherally derived
BDNF may have therapeutic effects on the spinal cord injury.
Materials and Methods
Animals and surgery
All surgical operations were performed on adult male Sprague-
Dawley (SD) rats under anesthesia with a mixture of 2%
Halothane (Veterinary Company of Australia, NSW) in O2 and
under the guidelines of the National Health and Medical Research
Council of Australia and approved by the Animal Welfare
Committee of Flinders University. The left sciatic nerve was
exposed after an incision was made in the mid thigh level of the
skin. The sciatic nerve was cut, the proximal end ligated with silk
suture and the wound closed with simple stitches. One week after
sciatic nerve lesion, animals were anaesthetized with Halothane.
Laminectomy was performed to remove the dorsal half of the
vertebra T8. Bilateral dorsal half spinal cord was lesioned as
described by Bradbury [71] with some modifications. A small
slit was made in the dura and the dorsal columns were crushed
with iris scissors which were inserted into the spinal cord until
reaching the mark of 1.5 mm. After crush, a sharp razor
blade marked at the depth of 1.5 mm passed through the wound
twice with the blade towards two different directions to make sure
all fibres in the dorsal column were cut. We verified that all
ascending sensory fibres were cut by lack of CTB staining in the
dorsal nuclei of medulla after injection of the tracer into the sciatic
nerve.
Fast Blue injection to label regenerated ascending
sensory neurons
One week before killing, rats were anaesthetized with
Halothane and laminectomy was performed on T8. Half ml of
3% FB (Sigma) was injected into the dorsal column of each rat
with a special syringe fixed on a stereotaxic frame to retrogradely
label regenerating neurons in the DRG. The injection site was
5 mm rostral to the spinal cord lesion site. The syringe (Hamilton)
was attached with a fine glass micro-needle. The dye was injected
slowly for 1 minute at a depth of 0.5–1 mm from the spinal cord
surface, the glass needle left inside for an additional 1 minute and
then withdrawn slowly. Rats were overdosed with pentabarbitone
and perfused through the heart with 4% paraformaldehyde (or
otherwise specified) and bilateral L4 and L5 DRG were dissected
and sectioned at 30 mm for the detection of FB+ neurons
(regenerating neurons).
Cholera Toxin B injection to label regenerated axons
Rats were anaesthetized four days before sacrifice, and the
proximal stump of left sciatic nerve was exposed. Half ml of 1%
CTB (List Biological Labs, USA) was injected into the nerve with
the glass micro-needle as described above. The glass needle was
kept inside the nerve for 1 minute after slow injection and left in
place for another 3 min before being slowly retracted. Two weeks
after spinal cord injury, rats were killed with an overdose of
pentobarbitone (80 mg/kg, i.p.) and perfused as above. The spinal
cord extending 5 mm rostral and 5 mm caudal to the center of the
injury site were then cryoprotected for 1 day in 30% sucrose
before being sectioned in parasaggital orientation at 30 mm, using
a freezing sliding microtome.
Immunohistochemistry of BDNF
Twenty four hours after spinal cord injury and 7 days after
sciatic nerve injury rats (n = 4) were killed with an overdose of
pentobarbitone (80 mg/kg, i.p.), and perfused through the heart
with 50 ml 1% sodium nitrate in 0.1 M phosphate buffer followed
by 300 ml of Histochoice tissue fixative MB (ASTRAL, Australia)
plus 2% formaldehyde. Spinal cord segments, including the lesion
sites, and bilateral L4, L5 DRG were dissected and post-fixed in
the same fixative containing 30% sucrose overnight at 4uC. The
spinal cords were cut longitudinally into 30 mm thick sections that
were transferred to PBS for free-floating processing. Spinal cord
sections were blocked in 20% NSS for 1 hour and incubated with
primary antibodies (rabbit polyclonal antibodies against recombi-
nant human BDNF, 1 mg/ml, Millipore) for 2 hours at room
temperature in antibody diluent containing 1% NSS or without
primary antibody as negative control. For DRG, BDNF
immunohistochemistry was performed as described previously
[12]. BDNF –ir DRG neurons was determined by counting the
total number of stained and unstained neuronal profiles from 5
sections at 100 mm intervals from each L5 DRG of rats with sciatic
nerve injury using the NIH Image 1.62 program. The positive
immunoreactivity was determined by threshold intensity above
background and the thresholds were kept constant for all samples.
Neurons which had an intensity higher than threshold were
considered positive. Data are reported as a percentage of BDNF-ir
neurons among total DRG neurons analyzed. Paired-sample t-test
was performed for comparison of the percentage of BDNF-ir
neurons of ipsilateral or contralateral sides.
ELISA detection of BDNF in spinal cord and DRG after
injury
To further quantify the levels of BDNF in the injured spinal
cord, we measured BDNF levels at different regions after spinal
cord injury. Rats (n = 8) were subjected to sciatic nerve lesion as
described above. One day after spinal cord lesion, rats were killed
with an overdose of pentobarbital and fresh spinal cord tissues
were dissected and frozen immediately in liquid nitrogen. In each
rat, the spinal cord was cut into left and right halves along
Posterior Median Sulcus and Anterior Median Fissure. Segments
(5 mm long) on both sides of the lesion site were collected. Two
samples of bilateral DRG (L4 and L5 together as one sample), and
the two segments of spinal cord at the lumbar enlargement were
also collected (Figure 2A).
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Ice cold homogenization buffer (100 mM Tris HCl, 1M NaCl,
4 mM EDTA.Na2, 0.5% Triton X-100) containing 1:25 freshly
made protease inhibitor solution (protease inhibitor cocktail tablet,
Roche, USA, 1 tablet dissolved in 1 ml H2O as stock solution) was
added quickly to tissues in a volume to weight ratio of 10 ml
solution per microgram of tissue. Tissues were homogenized with
a sonicator (Sonifier B-12, Connecticut) on ice and then
centrifuged 20,000 g for 30 min at 4uC. Supernatants were
collected to fresh tubes. Two-site enzyme linked immunoadsorbent
assay (ELISA) was performed to measure BDNF concentration
following a previously described protocol [72] [73]. The tissue
concentration of BDNF was calculated and standardized based on
protein concentrations of the spinal cord samples and recovery
rate of the internal standard sample [73]. The recovery rate was
calculated with the following formula: Recovery rate = (OD1-
OD2)/OD3x100%. OD1=Homogenates+BDNF standard,
OD2=Homgenates, OD3=BDNF standard. The values for the
BDNF concentrations in samples were calculated according the
formula generated from the trend line of standard curve. The
value was then multiplied by the dilution factor and then divided
by recovery rate to generate the final value for BDNF
concentration. Statistical analyses were carried out using Student’s
t-test and data were expressed as Mean6S.E.M.
Retrograde tracing combined with
immunohistochemistry of BDNF, p75NTR and p-CREB
BDNF is upregulated and p75NTR is down-regulated in
sensory neurons after sciatic nerve injury [12,35]. We proposed
that expression of BDNF and p75NTR in sensory neurons may
underlie the enhanced regeneration of ascending sensory neurons
triggered by sciatic nerve lesion. To test the possibility, we
correlated expression of BDNF and p75NTR with the regener-
ating neurons after conditioning sciatic nerve lesion. Five rats were
used for this study. All operations were performed on adult female
Sprague-Dawley (SD) rats for sciatic nerve lesion and spinal cord
injury as described above. Two weeks after spinal cord injury, the
rats were perfused and L4 and L5 DRG were dissected. The free-
floating sections at 30 mm will be stained for BDNF, p-CREB and
p75NTR as described previously[12,35].The sections were
examined under AX-70 fluorescence microscope. Three sections
were randomly selected from each animal and the percentages of
FB+/BDNF+ neurons, FB+/pCREB+ or FB+/p75+ neurons were
calculated.
BDNF antiserum treatment to the injured animals
To directly test the effect of endogenous BDNF on the axonal
regeneration of spinal cord after conditioning sciatic nerve lesion,
antiserum to BDNF was delivered to rats after conditioning sciatic
nerve lesion and spinal cord injury. All operations were performed
on adult female Sprague-Dawley (SD) rats for sciatic nerve lesion
and spinal cord injury as described above. A piece of gel foam
soaked with the antiserum to BDNF (n= 10) or normal sheep
serum (NSS) (n = 10) was placed on the spinal cord lesion site in
different group of rats. Antiserum or NSS were injected
intraperitoneally (i.p.) in the respective group of rats twice a week
(10 ml/g body weight). The concentration of immunoglobulin in
the BDNF antiserum was 10 mg/ml. The antiserum was fully
characterized and biologically active as tested in our previous
studies [36,74]. One group of rats (n = 4) whose sciatic nerves were
not injured served as negative control. After sciatic nerve lesion,
rats were still able to walk although the ipsilateral leg was affected
obviously. However, after spinal cord injury, the hind-limbs of all
rats were paralyzed. The urinary bladder had to be expressed
twice a day in the first week and most of the rats had blood in the
urine. From the second week after spinal cord injury, animals had
some recovery and blood was no longer present in the urine. FB
and CTB injection as tracers were performed as above. In a
separate experiment we injected FB to the dorsal column caudal to
the lesion site to label total ascending neurons (n = 5) in rats with
sciatic nerve lesion and spinal cord injury and treated with either
NSS (n = 5) or the BDNF antiserum (n= 5). This experiment was
to examine whether the BDNF serum treatment caused the death
of ascending sensory neurons. Each rat was perfused through the
heart with 50 ml 1% sodium nitrate, followed by 500 ml 4%
paraformaldehyde in 0.1 M phosphate buffer (PB). Spinal cord
segment including 1.0 cm tissue in both sides of lesion site and
bilateral lumbar L4 and L5 DRG were dissected. Spinal cords
were sectioned longitudinally at 30 mm and kept free-floating in
PBS until staining for CTB as below. DRG from both sides were
sectioned at 30 mm and mounted on slides consecutively. FB
labeled neurons on every third sections were counted. Only
neurons with clear nuclei labeling were counted. Average number
of neurons in each section was calculated and presented.
As it is known that sciatic nerve lesion causes upregulation of
GAP-43 [75,76] and phosphorylation of Erk [77], we sought to
examine whether endogenous BDNF plays a role in the
upregulation of GAP-43 and activated Erk, For this purpose, 8
rats were subjected to the sciatic nerve lesion and 4 rats were
treated i.p with either normal sheep serum or the BDNF antiserum
as described above. Two weeks after treatment, rats were perfused
and the ipsilateral and contralateral L4 and L5 DRG were
dissected and stained for GAP-43 and p- Erk as described below.
Three sections were randomly selected from each animal, Data
are reported as a percentage of GAP-43-ir or p-Erk –ir neurons
among total neurons in triplicate experiments.
Immunohistochemistry
For immunohistochemistry, free floating DRG or spinal cord
sections were blocked in 20% normal horse serum for 2 hours
before incubated in goat anti-CTB Subunit (1:5000, List Biological
Labs, USA), rabbit anti-p-CREB (1:200, Cell Signaling technol-
ogy), rabbit anti-p-Erk (1:200, Cell Signaling technology), mouse
anti-GAP-43(1:500, Sigma), rabbit anti-BDNF (1:200, Millipore),
mouse anti-p75NTR (MAB192, 1:500, Millipore) or rabbit anti-
CGRP (1:500, Millipore), respectively, or in appropriate combi-
nation for 24 hours. Appropriate Cy3 or Alexa 488 labeled
donkey anti- rabbit, anti-mouse or anti-sheep antibodies (1:200,
Jackson ImmunoResearch, West Grove, PA).were used to label
individual antigens. In some samples, nuclei were counterstained
with 49, 6-diamidino-2-phenylindole (DAPI). The specificity of the
Fluorescence microscopic immunohistochemical procedures was
validated by omitting the primary antibodies or by using
nonimmune serum instead of the primary antibodies. The sections
were observed in AX-70 microscopy with appropriate filters.
DRG explants culture in Matrigel
To study the neurotrophin influence on neurite outgrowth of
conditioning lesioned DRG in vitro, the left sciatic nerves of the
adult Sprague-Dawley rats (n = 8) were lesioned as described
above. The right sciatic nerves were left intact as controls. One
week after lesion, rats were killed with an overdose of
pentobarbital (80 mg/kg, i.p). Bilateral L4 and L5 DRG were
dissected and cut into eight pieces each in Ca2+ free Hank’s
solution. Matrigel (MatrigelTM Basement Membrane Matrix, BD
Bioscience, MD) was diluted with Dulbecco’s modification of
Eagle’s medium (DMEM, GIBCOBRL, Life Technologies, USA),
containing 10% fetal bovine serum (FBS, GIBCOBRL), 100
units/ml penicillin and 100 mg/ml streptomycin. The Matrigel
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mix was added with 1% antiserum against BDNF or NSS. DRG
pieces were planted into Matrigel mix in plastic culture dishes
(SARSTEDT, Australia) and cultured in 37uC for 48 hours in a
humidified incubator with an atmosphere of 5% CO2. Explants
were viewed with an inverted microscope (Olympus, Japan) and
photographed (Sony camera, CCD-IRIS, Japan). The lengths of
neurites in the images were measured with NIH Image 1.62
software.
DRG neuron culture
One week after sciatic nerve lesion, animals were anaesthetized
with Halothane again. Neurite outgrowth assays were performed
as described previously [26,55]. After culturing for 24 h, neurons
were fixed and immunostained for b -tubulin (1:500, Sigma).
Micrographs of immunostained cells were captured using an
Olympus AX70 (Olympus, Tokyo, Japan), and the length of the
longest neurite on each DRG neuron was measured using NIH
Image software. Results represent the average length of the longest
neurite from 180 to 200 neurons from at least five animals under
each condition.
Delivery of exogenous BDNF into the footpad of rats
During anaesthesia with 2% Halothane, 20 ml of BDNF
(100 mg/ml) or BSA(100 mg/ml) was injected into the footpad of
each rat with a special syringe for 1 minute each day. After 3 days
of injection a laminectomy was performed to remove the dorsal
half of the vertebra T8. Dorsal spinal cord lesion at T8 and FB
injection were performed as described. Two weeks after spinal
cord lesion animals were perfused as above and bilateral L4 and
L5 DRG were dissected and the number of Fast Blue labeled
neurons were counted as above. Injured spinal cord were
sectioned saggitally and longitudinally at 30 mm and sections were
stained for CGRP and GAP-43, respectively.
Delivery of exogenous BDNF into the sciatic nerve
Ten female Sprague Dawley rats were used for this experiment.
After puncturing the epineurium membrane with a fine suture
needle a pulled thin polyethylene catheter (tip diameter 150 mm)
was inserted into the sciatic nerve at the paravertebral region with
the tip towards the tail direction. The catheter was subcutaneously
linked to an Alzet osmotic pump (1007D) which was embedded
under the back skin. The pump was filled either with 100 ml
BDNF (0.5 mg/ml) or PBS. BDNF was delivered to sciatic nerve
for 7 days at 0.5 ml/hour. Three days after pump embedding, the
dorsal column was lesioned as above. Fast Blue injection and tissue
processing were as described above. The number of FB labeled
neurons was counted as above.
Behavioral tests
As the injection of BDNF in the foodpad before and after injury
resulted in significant regeneration of ascending sensory neurons,
we next tested whether the injection of BDNF in the footpad
improves motor recovery after spinal cord injury. To reduce the
variability of injury and to mimic clinical conditions, we produced
spinal cord contusion injury instead of dorsal column hemisection
injury. Adult Sprague-Dawley female rats, 8–10 weeks old were
used. Laminectomy was performed at T8 under anesthesia with
inhalation of 2% Halothane. Contusion injury was performed with
a New York University (NYU) weight-drop device, dropping the
10-g rod (2.5 mm in diameter) from 25 mm height on the exposed
spinal cord surface to generate moderate injury. Rats were
randomly allocated into two groups (marked as 1 and 2). Two
tubes containing BDNF or BSA were also marked with ‘‘1’’ and
‘‘2’’ respectively by a non-experimenter. Immediately after injury,
20 ml of solutions in tube ‘‘1’’ (BDNF, 100 mg/ml) or ‘‘2’’ (BSA,
100 mg/ml ) was bilaterally injected into the footpads of each rat
once per day for 5 consecutive days . A total of 16 rats were used
for contusion injury procedure, 8 in each group. One rat in the
each group was killed during the first week after SCI because of
poor general health. Seven animals in each group were used for
behavioral analysis. Hindlimb motor functions were assessed using
the open field (BBB) scoring system [78,79] postoperatively at 0, 3,
7, 14, 21 , 28 , 35 and 42 days after injury by two trained
observers. All observers were unaware of the group identity of the
animals.
Transport of biotinylated BDNF into the sciatic nerve
Soluble recombinant BDNF or BSA was labeled with biotin
using Easy-link biotin according to the protocol provided by the
manufacturer (Pierce). Biotinylated BDNF or biotinylated BSA
(2 mg/1 ml PBS) were injected into the footpad in adult rats (n = 2
each). Three and six hours after injection, the rats were perfused
with 4% paraformaldehyde. The skin of footpad and the entire
length of sciatic nerves were dissected and sectioned with a
cryostat. The sections were incubated in streptaivdin 2488 (1:500,
Jackson ImmunoResearch, West Grove, PA) 2 hours at room
temperature. The sections were mounted directly on glass slides
and observed under an AX70 Olympus microscope.
Microscopy and Quantitative analysis
Pictures for quantitative analysis were taken with Olympus AX
70 fluorescence microscope. Digital images were obtained using
the NIH 1.62 image program (NIH, Bethesda, MD). All data in
the text and figures are expressed as mean6S.E.M. To count the
number of regenerating neurons, every third section was selected
from each ipsilateral and contralateral DRG (L4 and L5) from
each animal. To measure the length of CTB+ axons that had
grown into the lesion cavity, five sections from each animal that
was treated with NSS or BDNF antiserum with the largest number
of CTB labeled fibers in the caudal spinal cord were used for
analysis. The length between caudal boundary of lesion site and
the axon end in the cavity was measured with NIH Image
program. Statistical comparisons were analysed using SPSS12.0
software. One-way ANOVA was used for testing the significance
of ELISA assay data and Student’s t tests were applied for
intergroup comparisons. Paired-sample t-test was performed for
side comparisons. p,0.05 was defined significant.
Supporting Information
Figure S1 Characterization of sheep antibody to BDNF by a
Western blot. 100 ng of BDNF, NGF, NT3 and NT4 were loaded
on 15% SDS gel, transferred to nitrocellulos membrane and
probed with the sheep antibody to BDNF. Lane 1: BDNF; lane 2:
NGF; lane 3: NT-3 and lane 4: NT-4. The sheep antibody only
recognizes BDNF but not NGF, NT-3 or NT-4.
Found at: doi:10.1371/journal.pone.0001707.s001 (0.35 MB TIF)
Figure S2 Effects of BDNF antiserum on the number of FB
labeled neurons in L5 DRG of rats with conditioning sciatic nerve
injury 1 week prior to spinal cord injury (n = 5 in each group). Fast
blue was injected into the dorsal column caudal to the lesion and
the number of neurons was counted from DRG as described in
Materials and Methods. A: A section from a DRG of a rat treated
with NSS. B: A section from a DRG of a rat treated with anti-
BDNF serum. C: A histogram shows no effects of BDNF
antiserum treatment on the number of FB labeled neurons in
DRG. Scale bar: 100 mm.
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Found at: doi:10.1371/journal.pone.0001707.s002 (3.09 MB TIF)
Figure S3 Effects of BDNF antiserum on the neurite outgrowth of
DRG explants. Ipsilateral and contralateral DRG one week after the
sciatic nerve lesion were dissected and cultured for 48 hours in
Matrigel in the presence of NSS or BDNF antiserum. A: An
ipsilateral DRG explant in the presence of NSS; B: A contralateral
DRG explant in the presence of NSS; C: An ipsilateral DRG explant
cultured in the presence of BDNF antiserum; D: A contralateral
DRG explant cultured in the presence BDNF antiserum; Arrows
indicate neurites; Scale bars: 200 mm, E Histogram shows the effect
of BDNF antiserum neutralization on the length of neurite growth of
DRG explants dissected from rats with sciatic nerve lesion. The
lengths of neurite outgrowth in the different groups of DRG explants
(n= 32 pieces of DRG for each group) were measured 48 hours after
culture of ipsilateral and contralateral DRG explants inMatrigel. IL:
ipsilateral, CL: contralateral.* P,0.05 compared with NSS treated
group (n=4/group).
Found at: doi:10.1371/journal.pone.0001707.s003 (0.94 MB TIF)
Figure S4 Retrograde transport of biotin-labeled BDNF injected
in the footpad. Six hours after footpad injection, the footpad skin
and sciatic nerve were dissected, sectioned and stained with
streptavidin conjugated Alexa-488. A, B, C: sections from rats
injected with biotin-BDNF in the foodpad. A: BDNF-containing
nerve fibres were detected in the epidermis of footpad of injected
side B: a sciatic nerve section 3 hours after biotin-BDNF injection;
C: a sciatic nerve section 6 hours after biotin-BDNF injection; D: a
sciatic nerve section 6 hours after biotin-BSA injection into the
footpad. Scale bar = 25 mm.
Found at: doi:10.1371/journal.pone.0001707.s004 (11.97 MB
TIF)
Figure S5 Effects of BDNF injection into the footpad on CGRP-
immunoreactive fibres in injured spinal cord. Micrographs (A and
F) were captured in the caudal-rostral orientation from left to
right. A: representative examples of CGRP immunoreactive
sensory axons from rats with BDNF injection into the footpad.
B, C, D, E are high-magnification micrographs taken from regions
marked as b, c, d, e in A, respectively. F: a section stained for
CGRP from a rat of BSA injection into the footpad. G, H, I are
high-magnification micrographs taken from regions marked as g,
h, i in F, respectively. As shown from these representative
micrographs, more CGRP nerve fibres were detected in the
vicinity of injury cavity in BDNF injected rats as compared to BSA
group. Scale bars in A and F: 100 mm; scale bar in B, C, D, E, G,
H and I : 25 mm.
Found at: doi:10.1371/journal.pone.0001707.s005 (2.88 MB TIF)
Figure S6 Effects of BDNF injection into the footpad on GAP-
43-immunoreactive fibres in injured spinal cords. A: a section from
a BDNF-treated rat; B: a high magnification micrograph taken
from the region marked with b in A; C: a section from a BSA
treated rat; D: a high magnification micrograph taken from the
region marked with d in C. Higher density and intensity of GAP-
43 staining were observed in BDNF-treated animals than those
from BSA-treated animals. Scale bars in A and C: 100 mm; scale
bar in B and D: 25 mm.
Found at: doi:10.1371/journal.pone.0001707.s006 (2.31 MB TIF)
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